SCIg for CIDP: A Patient Guide to Subcutaneous Immunoglobulin

Subcutaneous immunoglobulin therapy, often shortened to SCIg, is a maintenance treatment used for chronic inflammatory demyelinating polyneuropathy (CIDP). It delivers the same kind of antibody therapy as intravenous immunoglobulin (IVIg), but the medicine goes in under the skin rather than into a vein. For people whose CIDP is already controlled on IVIg, SCIg offers an alternative that can be done at home, on a more flexible schedule, and often with fewer of the systemic side effects that come with larger intravenous doses.

This guide covers what SCIg involves: how it works, how it differs from IVIg, who tends to do well on it, what the transition looks like, what side effects to expect, and the day-to-day realities of self-administered therapy.

What SCIg is and how it works in CIDP

SCIg uses the same active ingredient as IVIg: pooled immunoglobulin G antibodies collected from many human donors. In CIDP, the immune system mistakenly attacks the protective coating around peripheral nerves, called myelin. Immunoglobulin therapy helps calm that misdirected immune response and protect nerve function over time. The route of delivery is the main difference between IVIg and SCIg, and that route changes how the medicine behaves in the body.

With subcutaneous immunoglobulin, smaller volumes are infused into the fatty tissue just under the skin, typically through a small needle placed in the abdomen, thigh, or upper arm. The medicine then absorbs slowly into the bloodstream over hours and days. Because doses are smaller and more frequent, blood antibody levels stay relatively even from one week to the next rather than rising to a peak and then falling.

SCIg is currently approved for CIDP only as maintenance therapy, meaning it is used to keep symptoms stable after a patient has already responded to another treatment, usually IVIg. It is not approved as an induction therapy, the initial treatment used to bring active disease under control.

How SCIg differs from IVIg

The most practical differences between SCIg and IVIg show up in the schedule, the setting, and the side effects.

• Schedule. IVIg is usually given as a larger dose every three to four weeks, often in two to five hours per session. SCIg is typically given in smaller weekly doses, with each session lasting roughly one to one and a half hours.
• Setting. IVIg often requires an infusion center, hospital, or a home visit from an infusion nurse. SCIg, once a patient is trained, can be done independently at home, at work, or while travelling.
• Venous access. IVIg requires a usable vein for each infusion. Patients with difficult veins sometimes need a central line or port, which carries its own risks. SCIg does not require venous access at all.
• Side effects. IVIg can cause systemic effects such as headache, nausea, fatigue, or flu-like symptoms after a session. SCIg produces these less often, though local reactions at the infusion site, such as mild swelling or redness, are common.
• Antibody levels. IVIg produces a sharp rise and then a slow decline in antibody levels between doses, which some patients experience as a noticeable "wear-off" toward the end of the cycle. SCIg keeps antibody levels closer to steady.

Clinical studies in CIDP have repeatedly shown that, for patients already stabilized on IVIg, SCIg can maintain that benefit. Muscle strength, sensory function, and disability scores tend to remain stable, and relapse rates appear broadly comparable, particularly at higher maintenance doses. Local site reactions are more common with SCIg, but systemic reactions are consistently less common.

Who might be a good candidate for SCIg

SCIg suits some patients with CIDP better than others. A neurologist familiar with the disease is usually best placed to make the call, but a few patterns emerge in clinical practice.

SCIg tends to be a good fit when:

• Vein access has become difficult. Years of regular IVIg can leave veins scarred or unreliable. Avoiding the need for repeated venous access is a meaningful practical benefit.
• Wear-off symptoms appear between IVIg doses. Some patients feel weaker, more fatigued, or notice tingling and numbness in the days before the next infusion is due. Steadier antibody levels with SCIg can smooth out those fluctuations.
• Systemic side effects with IVIg are disruptive. Headaches, nausea, and infusion-day fatigue that take a day or two to recover from are common reasons patients ask about alternatives.
• Lifestyle and schedule favor flexibility. Patients who travel, work demanding hours, or care for family members sometimes find weekly self-administered sessions easier to plan around than full infusion days every few weeks.

IVIg tends to remain a better fit when:

• The structure of clinic visits and contact with infusion staff is preferred over managing therapy at home.
• Self-administration feels like more responsibility than is wanted at this point in life.
• A reliable home environment for the infusion is not in place, whether that means space, storage, or quiet time once a week.
• Manual dexterity, vision, or coordination would make self-infusion difficult, although this can sometimes be addressed with simpler preparation tools or with help from a family member.

Neither path is automatically right. The choice is meant to fit the person.

How the transition from IVIg works

Because SCIg is approved only for maintenance, the standard path is to start treatment with IVIg, stabilize the disease, and then move to SCIg if both the patient and the neurologist agree it makes sense.

The transition usually follows a familiar pattern. SCIg is started about one week after the last IVIg infusion, which keeps blood antibody levels high enough to avoid a dip during the switch. Weekly SCIg dosing is most common, though some regimens use injections two or three times per week with smaller volumes per session. The total weekly dose is typically chosen to match the previous IVIg dose on a one-to-one basis, divided across the new schedule.

Doses are individualized to the lowest amount that keeps symptoms controlled. Some patients do well on lower maintenance doses; others need higher doses to stay stable. Adjustments happen over time, based on how the patient feels day to day, how grip strength and walking measures track over follow-up visits, and how the neurologist scores disability and sensory function during examinations.

Most patients are watched closely in the first few months of SCIg therapy, since this is when fine-tuning matters most.

Self-administering at home

Self-administration is the practical advantage most patients associate with SCIg, and it is also the part of the transition that takes the most preparation.

Training is typically delivered by a specialty nurse, either in a clinic or during a home visit. Most patients need a few sessions to feel comfortable with the steps: preparing the equipment, choosing and rotating infusion sites, inserting the small needle or needles, running the infusion through a pump or by hand, and recording the dose. Many patients are independent within a few weeks. Family caregivers often learn the technique alongside the patient.

A few practical realities tend to come up early.

• Multiple infusion sites are common. Larger weekly doses may be split across two or more sites on the abdomen, thighs, or upper arms. Sites are rotated to avoid irritating the same spot repeatedly.
• Pre-filled syringes can help with dexterity. Drawing the medicine from a vial requires fine hand control. Patients with hand weakness, vision changes, or coordination issues often find pre-filled syringes simpler to prepare.
• Equipment is portable. Small infusion pumps run the medicine at a set rate. Some patients use a manual technique, infusing by hand over several minutes.
• Records matter. Keeping notes on dose, date, infusion site, and any reactions helps the care team fine-tune the regimen.

Most patients describe the learning curve as steep at first and routine within a month or two.

Side effects: what to expect and when to call

SCIg has a different side-effect profile from IVIg, and knowing what to expect helps patients tell routine reactions apart from ones that warrant a call to the care team.

• Local infusion-site reactions are the most common side effect. Redness, swelling, mild pain, or a small lump under the skin tend to be most noticeable in the first weeks of therapy and to lessen as the body adjusts. Cool compresses, gentle massage, and rotating sites help.
• Systemic side effects happen less often than with IVIg. Headache, nausea, fatigue, and flu-like symptoms can still occur but are reported less often. Pre-medication, common with IVIg, is rarely needed for SCIg.
• Serious side effects are uncommon but possible. All immunoglobulin products carry a small risk of blood clots, kidney problems, breakdown of red blood cells, and a non-infectious inflammation around the brain and spinal cord. These risks appear in the prescribing information and are discussed as part of treatment planning.
• Allergic reactions are rare. Patients with a known severe allergy to immunoglobulin products or specific stabilizing ingredients should not use SCIg.

Symptoms that should prompt a same-day call to the care team include sudden severe headache, chest pain, unexplained shortness of breath, leg swelling or warmth on one side, or dark urine.

What if SCIg isn’t working

CIDP behaves differently in different people. Some patients do well on a stable maintenance dose for years. Others see their needs change, either because the disease quiets down or because symptoms threaten to return.

If symptoms begin to worsen on SCIg, the first step is usually a dose increase. Many patients re-stabilize at a higher weekly dose without changing therapy. The care team may also look for other explanations, such as a recent illness, missed doses, or a change in absorption.

If higher SCIg doses are not enough, a return to IVIg, alone or combined with another treatment, may be considered. Switching back is not a failure; it simply means the route that suits the patient at one stage of the disease may not be the right one at another.

Persistent worsening warrants prompt review with the neurologist rather than adjustments at home.

Where CIDP research is heading

Researchers continue to study new ways to treat CIDP, including new immunoglobulin formulations and new ways of delivering existing therapies. Clinical trials are ongoing to better understand how these options compare and how they may help people living with the condition. Patients interested in current research can discuss the available options with their healthcare provider.

Living with SCIg long-term

SCIg therapy works best when it fits into a sustainable routine. Patients who do well on it tend to settle into a consistent weekly schedule, build a small supply of equipment and a reliable place to infuse, and stay in regular contact with a care team that can troubleshoot site reactions, supply issues, or dose questions.

Quality-of-life research suggests that the convenience of home-based therapy and the reduction in systemic side effects translate, for many patients, into more predictable weeks. There is no infusion day to plan around, no recovery period after each session, and no need to schedule around clinic availability. Fatigue, pain, and cognitive symptoms of CIDP do not disappear, and SCIg is not a cure, but the disruption that treatment itself adds to daily life tends to be smaller. Practical guidance on energy management, work, and emotional health is covered in a broader guide on living with CIDP.

Frequently asked questions

Is subcutaneous as good as IVIg?

For people with CIDP already stabilized on IVIg, clinical studies and pooled analyses suggest that subcutaneous therapy can maintain that benefit. Muscle strength, sensory function, and disability scores tend to stay stable, and relapse rates appear broadly comparable, especially at higher maintenance doses. The choice between routes is less about which works better overall and more about which fits the patient.

Can you start CIDP treatment with SCIg?

SCIg is currently approved for CIDP as a maintenance therapy, not as an induction treatment for active disease. The standard path is to start with IVIg to bring symptoms under control, then transition to SCIg for ongoing maintenance if both the patient and the neurologist agree it is a good fit. Research into SCIg as a first-line option is ongoing, but it is not the approved use today.

What is the difference between SCIg and IVIg for CIDP?

Both deliver the same kind of antibody therapy. IVIg goes into a vein, typically every three to four weeks in longer sessions at an infusion center. SCIg goes under the skin, usually weekly in shorter sessions, and can be self-administered at home after training. SCIg keeps antibody levels steadier and tends to cause fewer systemic side effects; local reactions at the infusion site are more common.

How often does SCIg need to be given?

Most patients with CIDP on SCIg receive weekly infusions, though some regimens divide the dose into two or three sessions per week with smaller volumes per session. A smaller number of patients use less frequent schedules. The exact frequency is set by the neurologist based on the dose needed, the patient’s tolerance, and how the regimen fits into daily life.

Talking through SCIg with a care team

Whether SCIg is the right next step depends on a mix of medical and personal factors: how stable the disease is on current treatment, how IVIg is being tolerated, whether vein access is becoming difficult, what the home situation looks like, and how the patient feels about taking on self-administration. None of this is decided in a single appointment.

A few questions are often useful to bring to the conversation. How does the current treatment compare with what SCIg would offer in this case? What does the transition timeline look like? How will training and supplies be set up? Who is the first point of contact when something goes wrong? Broader background on the full range of CIDP treatment options, and on how IVIg for CIDP works, can help frame that discussion.